Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Dynavax Technologies Corporation

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Dynavax Technologies Corporation (“Dynavax” or the “Company”) DVAX between April 26, 2012 and June 10, 2013 (the “Class Period') have until August 19, 2013 to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Northern District of California.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU PURCHASED DYNAVAX STOCK PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Dynavax is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Complaint alleges that during the Class Period the Company issued false and/or misleading statements and/or failed to disclose that: (1) the Phase 3 clinical trial for HEPLISAV -- the Company's investigational adult hepatitis B vaccine -- was flawed because the trial demographics were not representative of the U.S. population; (2) the HEPLISAV clinical trial was lacking the one-year safety follow-up typically required for vaccines; (3) the HEPLISAV trial was lacking information concerning concomitant use with other vaccines; (4) the size of the clinical trial's safety database was inadequate to rule out rare adverse autoimmune events; (5) Dynavax failed to provide the FDA with sufficient data concerning its manufacturing processes and controls for HEPLISAV; and (6) based on the foregoing, defendants lacked a reasonable basis for their positive statements about the Company or its outlook, including statements about its launch of HEPLISAV in 2013.

To learn more about this action or if you purchased Dynavax stock prior to the Class Period and have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.